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Abstract
Low maternal circulating concentrations of placental growth factor (PlGF) are one of the hallmarks of human
pregnancy complications, including fetal growth restriction (FGR) and early-onset pre-eclampsia (PE). Currently,
PlGF is used clinically with other biomarkers to screen for high-risk cases, although the mechanisms underlying
its regulation are largely unknown. Placental endoplasmic reticulum (ER) stress has recently been found to be
elevated in cases of FGR, and to an even greater extent in early-onset PE complicated with FGR. ER stress
activates the unfolded protein response (UPR); attenuation of protein translation and a reduction in cell growth
and proliferation play crucial roles in the pathophysiology of these complications of pregnancy. In this study, we
further identified that ER stress regulates release of PlGF. We first observed that down-regulation of PlGF protein
was associated with nuclear localization of ATF4, ATF6𝛂 and ATF6𝛃 in the syncytiotrophoblast of placentae from
PE patients. Transcript analysis showed a decrease of PlGF mRNA, and an increase from genes encoding those UPR
transcription factors in placentae from cases of early-onset PE, but not of late-onset (>34weeks) PE, compared
to term controls. Further investigations indicated a strong correlation between ATF4 and PlGF mRNA levels only
(r =− 0.73, p< 0.05). These results could be recapitulated in trophoblast-like cells exposed to chemical inducers of
ER stress or hypoxia–reoxygenation. The stability of PlGF transcripts was unchanged. The use of small interfering
RNA specific for transcription factors in the UPR pathways revealed that ATF4 and ATF6𝛃, but not ATF6𝛂, modulate
PlGF transcription. To conclude, ATF4 and ATF6𝛃 act synergistically in the negative regulation of PlGF mRNA
expression, resulting in reduced PlGF secretion by the trophoblast in response to stress. Therefore, these results
further support the targeting of placental ER stress as a potential new therapeutic intervention for these pregnancy
complications.
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Pre-eclampsia and fetal growth restriction (FGR) are
two major causes of neonatal mortality and morbidity
[1].Many potential causes have been proposed, although
the pathological mechanisms underlying these disorders
are still not fully understood. Hence, effective treatments
remain elusive [2,3]. Pre-eclampsia is a multi-system,
heterogeneous syndrome and increasingly two forms are
recognized, early- and late-onset [4,5]. Roberts and Red-
man stated in 1993 that PE ’starts with the placenta
and ends with the endothelium’ [6]. This hypothesis has
been developed further [7], but remains the mainstay
of current understanding of the pathophysiology. The
early-onset form is commonly associated with growth
restriction and severe placental pathology. A failure in
spiral artery remodelling is thought to lead to poor utero-
placental perfusion and intermittent placental hypoxia.
Consequently, the placenta suffers oxidative stress, caus-
ing the release of factors that have systemic actions
on various maternal organs. By contrast, spiral arte-
rial and placental pathology are minimal in late-onset
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pre-eclampsia. It is thought that in these cases themother
carries a genetic predisposition to cardiovascular disease
that renders her endothelium hypersensitive to factors
released from a relatively normal placenta. Since mater-
nal endothelial cell activation appears to be the common
end-point that unifies various features of the syndrome,
attention has focused on an imbalance between angio-
genic and anti-angiogenic factors in the maternal circu-
lation as one of the underlying mechanisms [2,8].
The pro-angiogenic factor, placental growth factor
(PlGF), is a homodimeric glycoprotein with signifi-
cant homology to vascular endothelial growth factor
A (VEGF-A), which was originally identified in the
human placenta [9]. It is an important regulator of
angiogenesis and vasculogenesis [10] and four variants,
−1, −2, −3 and −4, have been identified so far. All
are primarily expressed in the placenta, predominately
localized to the syncytiotrophoblast and endothelial
cells [11–15]. PlGF-1 and PlGF-3 are secreted forms,
whereas PlGF-2 and PlGF-4 are membrane-bound
because of their heparin-binding domains. PlGF binds
to VEGF receptor 1 (VEGFR1), also known as Flt-1,
thereby initiating kinase mediated signalling [16].
In cases of FGR and pre-eclampsia, maternal cir-
culating PlGF concentrations are reduced [17,18],
particularly in early-onset pre-eclampsia. Levels of
other factors in the angiogenic balance are also altered.
Anti-angiogenic factors, including the soluble Fms-like
tyrosine kinase-1 receptor (sFlt-1) that binds VEGF-A
and soluble endoglin (sEng), are increased in mater-
nal blood before the onset of pre-eclampsia [18,19].
Changes in placental release are thought to under-
lie these alterations, as immunostaining for sFlt-1 is
increased, and for PlGF decreased, in pre-eclamptic
placentae compared to normal controls [20]. Similarly,
sFlt-1 is increased and PlGF decreased in cultured
trophoblast cells or placental villous explants exposed
to oxidative stress [21]. The pro-angiogenic factors
VEGF-A and PlGF promote the survival and pro-
liferation of endothelial cells and induce vascular
permeability [22,23]. The binding of sFlt1 to free
VEGF-A and PlGF in the circulation reduces their
availability and can act as a dominant-negative receptor,
thereby causing endothelial cell dysfunction, leading
to hypertension, proteinuria and the other maternal
systemic symptoms of pre-eclampsia [24,25]. As a
result, measurement of maternal circulating PlGF early
in pregnancy has been used clinically to screen for both
early-onset pre-eclampsia and FGR [17].
The level ofPlGF transcripts is regulated by transcrip-
tion factors, including metal responsive transcription
factor 1 (MTF-1), nuclear factor-κB (NF-κB) [26–28],
as well as microRNA-125b in hepatocellular cancer
[29]. In addition, in placental tissues the transcription
factor glial cell missing 1 (GCM1) and the protein kinase
A (PKA) signalling pathway up-regulate its expression
[28]. The latter acts through cAMP-responsive element
binding proteins (CREBs) [30]. However, the molecular
mechanisms leading to down-regulation of PlGF in the
pathogenesis of pre-eclampsia and FGR remain elusive.
Placental endoplasmic reticulum (ER) stress has
recently been recognized as playing a central role
in the pathophysiology of early-onset pre-eclampsia
and FGR, but not in late-onset pre-eclampsia [31,32].
The ER is the major organelle for the biosynthesis
of polypeptide hormones, growth factors and plasma
membrane proteins, and initiates their folding and
post-translational modifications. Overloading of the
ER with nascent proteins, or perturbation of its ionic
homeostasis through a variety of pathological stimuli,
can lead to an imbalance between the protein load
and the capacity of the folding machinery. As a result,
unfolded or misfolded proteins accumulate in the lumen,
a condition known as ER stress [36]. This leads to acti-
vation of signalling pathways, collectively known as
the unfolded protein response (UPR). Initially, the UPR
aims to restore normal ER function but, if the attempt
fails, apoptotic cascades are activated to eliminate dam-
aged cells. The UPR comprises three highly conserved
signalling pathways, including PERK–eIF2α–ATF4,
which attenuates non-essential protein synthesis and
increases antioxidant defence systems; ATF6, which
up-regulates ER chaperones (GRP78 and GRP94) to
increase folding capacity; and IRE1–XBP1, which
increases phospholipid biosynthesis and promotes mis-
folded protein degradation [33]. These pathways are
activated sequentially in a severity-dependent manner
[31,34].
In addition, activation of the transcription factors
in the UPR pathways regulates expression of genes
involved in a wide range of cellular functions, such as
redox processes, amino acid metabolism and angiogen-
esis [35–39]. In this study, we elucidated a novel mecha-
nism by which ER stress potentially modulates maternal
endothelial cell activation via down-regulation of PlGF
gene expression in early-onset pre-eclampsia.
Materials and methods
Study population and placental sample collection
All placental samples were obtained with local ethi-
cal permission and the patients’ informed written con-
sent. The detailed criteria for recruitment of patients
for this study have been described previously [40].
Briefly, the control group was from healthy normoten-
sive term patients who displayed no abnormalities on
routine scans, while the pre-eclamptic group was from
patients with new-onset hypertension (≥140/90mmHg)
observed on at least two separate occasions, 6 h or more
apart, combined with proteinuria (a 24 h urine sample
showing≥ 300mg/24 h). Women with pre-pregnancy
diseases such as hypertension, diabetes mellitus or
pre-existing renal disease were excluded. All placen-
tae were obtained from elective, non-laboured caesarean
deliveries. For each placenta, four to six small pieces of
tissue from separate lobules were rinsed three times in
saline, blotted and snap-frozen in liquid nitrogen within
10min of delivery; the samples were stored at −80 ∘C.
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The clinical features of the pregnancies were described
previously [32].
Cell culture
Human choriocarcinoma JEG-3 and BeWo cells were
cultured as described previously [34,41].
Western blot analysis
Western blots were performed on both cell lysates and
culture media to quantify relative total levels or phos-
phorylated levels of specific proteins. The details of anti-
bodies and procedures are described in Supplementary
materials and methods (see supporting information) and
in a previous study [34].
In vitro hypoxia–reoxygenation experiments
For hypoxia–reoxygenation (H/R) challenge, cells were
cultured in normal growth medium without serum in
an incubator that allowed precise and variable control
of oxygen (ExVivo, BioSpherix, Lacona, NY, USA)
and the experiments were performed as described in a
previous study [32].
Quantitative real-time RT–PCR analysis
Total RNA was isolated using RNeasy Mini Kits
(Qiagen, Manchester, UK), according to the manufac-
turer’s instructions, and the quantitative PCR performed
using SYBRGreen JumpStart kits (Sigma, Dorset, UK).
Details of the primer sequences (Table S1) and other
procedures are described in Supplementary materials
and methods (see supporting information). The PlGF
primers detected three of the four isoforms of PlGF,
including PlGF-1, −2 and −3.
Small RNA interference
siRNA-mediated knockdown of transcripts of inter-
est in BeWo cells was performed using Lipofectamine
RNAiMAX transfection reagent (Life Technologies,
Paisley, UK) for 48 h, according to the manufacturer’s
instructions. Details of siRNAs and the experimental
procedures are described in Supplementary materials
and methods (see supporting information)
Immunohistochemistry
Immunohistochemistry was performed as previously
described [42]. The details of antibodies and specific
conditions for each antibody are described in Supple-
mentarymaterials andmethods (see supporting informa-
tion).
Statistical analysis
Differences were tested using non-parametric
Kruskal–Wallis test with Dunn’s multiple compari-
son test. Correlations between PlGF mRNA and ATF4
or ATF6α or ATF6β mRNAs were tested using Pear-
son’s correlation. Power regression lines were fitted to
display relationships. For cell culture experiments, both
the Mann–Whitney test and two-tailed Student’s t-test
were used as appropriate. All statistical analyses were
performed using GraphPad Prism v. 6.0, with p≤ 0.05
considered significant.
Results
Severity of ER stress is negatively correlated
with PlGF transcript and protein levels
in pathological placentae
Oxidative stress is a strong inducer of ER stress [34]
and lowers PlGF in the placenta [21]. We therefore
investigated the potential role of ER stress in the reg-
ulation of PlGF synthesis. In the placenta, PlGF is
predominately localized in the syncytiotrophoblast,
and its level is reduced in placentae from cases of
early-onset pre-eclampsia (Figure 1). We first examined
activation of the three UPR pathways using immuno-
histochemistry. Interestingly, the activity of PERK
(which is indicated by ATF4), ATF6 (which has two
isoforms, α and β), and IRE1α were all increased, and
located mainly in the syncytiotrophoblast and fetal
endothelial cells (Figure 1). ATF4, ATF6α and ATFβ
are transcription factors, and their activation promotes
nuclear translocation. Indeed, increased ATF4 and
ATF6α and ATFβ immunoreactivity was found mainly
in the syncytiotrophoblastic nuclei, implicating them in
transcriptional regulation in the pathological placentae.
We next investigated whether the low level of PlGF
in placentae from pre-eclamptic patients was regulated
at the transcription level. Therefore, PlGF mRNA
was measured in placentae from normotensive term
controls (n= 7), early-onset pre-eclampsia (n= 10)
and late-onset pre-eclampsia (n= 8). A significant
reduction of PlGF mRNA was observed in placentae
from early-onset pre-eclampsia, but not in those from
late-onset pre-eclampsia, where levels were indistin-
guishable from the term controls (Figure 2A). Analysis
of ATF4, ATF6α and ATF6β transcripts revealed that all
three were similarly significantly elevated in placentae
from early-onset pre-eclampsia, but not in those from
the late-onset cases (Figure 2A).
To test for any relationship between these ER
stress-mediated transcription factors and the PlGF
mRNA level, correlations were plotted for PlGF
mRNA against the transcript levels of ATF4, ATF6α
and ATF6β. We observed a significant relationship
(p< 0.001) between ATF4 and PlGF transcripts, with
the correlation coefficient reaching −0.733 (R2 = 0.537)
(Figure 2B). By contrast, no significant relationship was
observed for ATF6α and ATF6βmRNA (see supplemen-
tary material, Figure S1). This result strongly suggests
a potential role of ER stress in the negative regulation
of PlGF transcription mediated by ATF4. Therefore,
cell culture models and ER stress inducers were used to
investigate the potential mechanism further.
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Figure 1. Placental ER stress is associated with lower PlGF expression in pre-eclamptic placentae. Immunohistochemical staining showed
the expression and localization of PlGF, ATF4, ATF6α, ATF6β and P-IRE1α in both pre-eclamptic and normotensive control placental sections
using corresponding specific primary antibodies. Negative controls were performed by omitting the primary antibodies; scale bar= 100 μm;
arrows, nuclear localization of proteins
ER stress induces a severity-dependent reduction
in PlGF secretion and gene expression
in trophoblast-like cell lines
In order to eliminate cell type-specific and drug-specific
effects, two human choriocarcinoma cell lines, JEG-3
and BeWo, and two ER stress inducers, tunicamycin
(Tm, an N-linked glycosylation inhibitor) and thapsi-
gargin (Tg, an inhibitor of sarco-endoplasmic reticulum
Ca2+ ATPase), were used for studies in vitro. We have
previously reported a dose–response effect of tuni-
camycin on the activation of ER stress pathways and
apoptosis in JEG-3 cells [31]. Therefore, the results
presented in Figure 3A are from BeWo cells. Doses
of tunicamycin of up to 0.63 μg/ml cause minimal
cell death (3.2%), whereas 1.25 μg/ml and 2.5 μg/ml
cause 40% and 56%, respectively [34]. We performed
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Figure 2. Placental ER stress is associated with lower PlGF mRNA levels in pre-eclamptic placentae. (A) Quantitative real-time RT–PCR was
used to measure transcript levels of PlGF , ATF4, ATF6α and ATF6β in early-PE, late-PE and NTC placentae; data are presented as Dot-plots
with median; the differences among early-PEs, late-PEs and NTCs was analysed by a non-parametric Kruskal–Wallis test with Dunn’s
multiple comparison test; early-PE, n= 11; late-PE, n= 8; and NTC, n= 7; *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001. (B) The correlation between
ATF4 and PlGF mRNA levels was plotted for all placental samples; a power regression line was fitted to display the relationship between
the two transcripts; ***p≤ 0.001
a similar dose–response study for thapsigargin, and
found an equivalent effect in induction of apoptosis.
Doses< 100 nM caused minimal cell death after 24 h,
and so this was the maximum concentration used for
subsequent experiments. Increasing concentrations
of thapsigargin induced dose-dependent activation
of all three UPR pathways, while with tunicamycin
the PERK-eIF2α and IRE1α arms were clearly acti-
vated, but not the ATF6α pathway. However, ATF6α
is a glycoprotein containing three N-glycosylation
sites at the C-terminus, and under-glycosylation has
been shown to increase its transcriptional activity
[43]. In Figure 3A, a gradual reduction in ATF6α
electrophoretic mobility was observed as the concen-
tration of tunicamycin increased, indicating a loss of
N-glycosylation and thereby an elevation of its tran-
scriptional activity. Both ATF6α(p50) and ATF6α(p90)
undergo proteosomal-mediated degradation upon acti-
vation [44,45]. This might explain why ATF6α protein
was greatly reduced at the lethal dosage of tunicamycin
(2.5 μg/ml).
In order to reveal the activity of these pathways in
response to tunicamycin, the downstream effectors of
the PERK–eIF2α, ATF6α and IRE1α pathways, viz.
ATF4, GRP78 and XBP-1, respectively, were examined.
Under ER stress, phosphorylation of eIF2α mediates
an increase in transcription and translation of ATF4
[46]; activation of ATF6α up-regulates GRP78 gene
expression [47], while the increased endoribonuclease
activity of activated IRE1α facilitates XBP-1 mRNA
splicing [48]. As can be seen in Figure 3B, there was a
dose-dependent increase of ATF4, GRP78 and splicing
of XBP-1mRNA, confirming activation of all three UPR
pathways in response to tunicamycin. Crucially, increas-
ing severity of ER stress was closely associated with
decreased secretion of PlGF by the cells (Figure 3C).
The reduced levels of PlGF mRNA measured in
placentae from early-onset pre-eclampsia in Figure 2A
suggest that the decrease in maternal blood concentra-
tions PlGF seen in pre-eclampsia are likely to result
from the reduction of PlGF mRNA.We therefore exam-
ined PlGF transcripts under ER stress in both BeWo
and JEG-3 cells. Indeed, PlGF mRNA was reduced in
an ER stress severity-dependent manner in both cell
types (Figure 3D), demonstrating a similar profile to
the secreted PlGF (Figure 3C). Both transcription and
RNA degradation contribute to the transcript level.
PlGF mRNA stability was investigated using the global
transcription inhibitor, actinomycin D (Act-D). We
treated cells in the presence or absence of tunicamycin
and followed the degradation of the PlGF transcripts
over time. As shown in Figure 3E, PlGF mRNA levels
under ER stress were unchanged in the absence of tran-
scription. This indicates that the reduction was not due
to increased mRNA degradation and hence the observed
changes in PlGF transcript level were due to changes
in transcription. Furthermore, comparison of the rates
of PlGF mRNA decline induced by tunicamycin and
Act-D alone shows that the rate with tunicamycin was
relatively linear, whereas with Act-D there was a 60%
decrease in the first 3 h.
Transcription of PlGF is negatively regulated
by ATF4 and ATF6β
The results presented in Figure 2B indicate a strong
negative correlation between the levels of the
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Figure 3. ER stress induces a severity-dependent reduction of PlGF protein and mRNA in trophoblastic-like cells. (A) Dose–response study
of ER stress inducers, tunicamycin (Tm) and thapsigargin (Tg) in BeWo cells: the severity of ER stress, which is indicated by the degree of
activation in three highly conserved UPR pathways PERK, IRE1 and ATF6, was measured by western blotting analysis, with primary antibodies
specific to phosphorylated or total protein levels of P-eIF2α (Ser51), eIF2α, P-IRE1α (Ser724), IRE1α, ATF6α (p90) and ATF6α (p50); Ponceau
S staining was used to show equal protein loading of the samples. (B) Activation of three UPR pathways in the tunicamycin dose–response
study was indicated by their downstream effectors: ATF4 for PERK; GRP78 for ATF6 and XBP-1 mRNA splicing for IRE1; western blotting
was used to measure protein levels of ATF4 and GRP78 and β-actin was used as the loading control, while RT–PCR was used to analyse
mRNA splicing of XBP-1. (C, D) ER stress severity-dependent down-regulates PlGF release and gene expression in trophoblast-like cells.
(C) ELISA was used to quantify the amount of PlGF released by BeWo cells after treating with various concentrations of ER stress inducers
for 24 h; data are presented as mean± SEM, n= 4. (D) Quantitative RT–PCR was used to measure PlGF mRNA levels in both BeWo and
JEG-3 cells after treatment with tunicamycin or thapsigargin for 24 h; data are presented as mean± SEM, n= 4/group; *p< 0.05 compared
to control. (E) Decrease of PlGF mRNA under ER stress is not the result of increased RNA degradation: PlGF mRNA stability was analysed
using the global transcriptional inhibitor actinomycin D (1 μg/ml) in the presence or absence of Tm (0.625 μg/ml); qRT–PCR was used to
measure PlGF mRNA level in a time-course study, in which samples were collected after 0, 1, 3, 6, 9, 12, 18 and 24 h; data are presented
as mean± SEM, n= 3/time point/group
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Figure 4. Expression of PlGF mRNA is negatively regulated by ATF4 in a trophoblastic-like cell. (A) Dose-dependent increase of ATF4 mRNA
under ER stress: BeWo cells were cultured in normal growth medium without serum in various concentrations of the ER stress inducers
tunicamycin (Tm) and thapsigargin (Tg) for 24 h; normalized ATF4 mRNA level was measured by qPCR; data are presented as mean± SEM,
n= 3; *p< 0.05 compared to control. (B) Negative correlation between PlGF and ATF4 mRNA relative levels in BeWo cells in response to
ER stress; the correlation was plotted using the data in Figures 4A and 3D. (C) siATF4 greatly reduces ATF4 protein level in both control and
treated conditions: cell lysates were isolated and subjected to western blotting analysis with ATF4-specific antibody; GRP78 level was used
to indicate existence of ER stress upon thapsigargin treatment and β-actin was used as the protein loading control. (D) Suppression of ATF4
increases PlGF mRNA: BeWo cells were transfected with non-targeting control small interfering RNAs (siCon) or ATF4 siRNA (siAtf4); after
48 h of transfection, the cells were treated with thapsigargin for 24 h; PlGF and ATF4 mRNA levels were measured by quantitative RT–PCR
normalized to internal controls, TBP and GAPDH; data are presented as mean± SEM; n= 8; **p< 0.01
transcription factor ATF4 and PlGF mRNA in pla-
centae from pre-eclampsia. Therefore, we examined
whether the same correlation existed in the cell cul-
ture model in response to ER stress. There was a
dose-dependent increase of ATF4 mRNA upon increas-
ing concentrations of tunicamycin (Figure 4A), which
correlated closely (R2 = 0.91) with the decline in PlGF
mRNA (Figure 4B).
To provide direct evidence of a role of ATF4 in the reg-
ulation of PlGF transcription, we specifically knocked
down ATF4 transcripts using siRNA. Application of
siATF4 reduced ATF4 mRNA and protein by> 70%
in both untreated and thapsigargin-treated conditions
(Figure 4C; see supplementary material, Figure S2A).
siATF4 treatment also up-regulated PlGF mRNA by
34% in untreated cells (Figure 4D). By contrast, in the
presence of thapsigargin, PlGF transcripts were sup-
pressed by 35% in siCon cells, but were restored by over
75% in siATF4-treated cells (Figure 4D), confirming the
role of ATF4 in the negative regulation of PlGF tran-
scription.
In addition to ATF4, the transcription factors ATF6α,
ATF6β and XBP-1 are also involved in UPR pathways
in response to ER stress. Nuclear localization of ATF6α
and ATF6β in placentae from early-onset pre-eclampsia
(Figure 1) was increased and our previous studies
showed increased spliced XBP-1 (activated form)
mRNA in similar placentae [31]. We therefore knocked
down ATF6α, ATF6β and XBP-1 transcripts using
specific siRNAs. ATF6α, ATF6β and XBP-1 mRNAs
were suppressed by> 70% (see supplementary material,
Figure S2B, C). siATF6α treatment did not affect ATF6β
expression and vice versa (see supplementary material,
Figure S2B). Levels of the PlGF transcript were not
affected by siATF6α and siXBP-1 in both untreated and
thapsigargin-treated cells (Figure 5A, D). However, fol-
lowing siATF6β treatment, we observed a 65% increase
of PlGF mRNA in untreated cells, although the increase
did not reach statistical significance (p= 0.11) in the
thapsigargin-treated condition (Figure 5B).
Activated ATF6β has been shown to interact with
ATF6α, thereby inhibiting UPR-mediated gene expres-
sion [49]. Therefore, we investigated whether ATF6β
might modulate ATF6α- or ATF4-mediated PlGF
gene expression. siRNA-mediated double knockdown
of ATF6β+ATF4 and ATF6α+ β genes was per-
formed in the presence of thapsigargin. Application of
siATF6α+ β reduced ATF6α and ATF6β transcript lev-
els by 80% and 60%, respectively (see supplementary
material, Figure S2B). Knockdown of both ATF6α and
β did not significantly enhance PlGF mRNA in either
untreated or thapsigargin-treated cells (Figure 5C).
By contrast, in the siATF6β+ siATF4 double knock-
down, we observed a synergistic effect in up-regulation
of PlGF transcript levels. In comparison to siCon,
siATF6β+ siATF4 caused a 2.4-fold increase of PlGF
mRNA in both untreated and thapsigargin-treated cells
(Figure 5C).
Hypoxia–reoxygenation modulates PlGF
transcription inhibition, which is partially regulated
through ATF4 and ATF6β
Poor placentation induces hypoxia–reperfusion, result-
ing in placental oxidative stress, a key feature of the
pathophysiology of growth restriction and early-onset
pre-eclampsia [50]. Therefore, an in vitro model of
repetitive hypoxia–reoxygenation (rHR), in which
cells were repeatedly exposed to 6 h cycles of 1%
and 10% O2 for 24 h, was used as a more physio-
logical model of stress. PlGF mRNA was reduced
∼50% after 24 h of rH/R (Figure 6A). Application of
siATF4 and siATF6β, individually or in combination,
partially restored PlGF mRNA levels but was not as
efficient as when used with the ER stress-inducer thap-
sigargin (Figure 6B). These results suggest that other
transcription factors, such as MTF1 and NF-κB, may
contribute to regulation of PlGF transcription under
oxidative stress.
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Figure 5. ATF6β acts synergistically with ATF4 in down-regulation of PlGF transcription, while ATF6α and XBP-1 are not involved in the
regulation: siRNAs specific for siATF4, ATF6α, ATF6β and siXBP-1 were used individually or in a combination to knock down corresponding
gene(s) for 48 h before treating with thapsigargin for an additional 24 h in BeWo cells; PlGF mRNA levels were measured by qPCR normalized
to internal controls, TBP and GAPDH; data are presented as mean± SEM; n= 4–8; **p< 0.01. (A) ATF6α; (B) ATF6β; (C) ATF4–ATF6α–ATF6β;
(D) XBP-1
Figure 6. Expression of PlGF is partially regulated by ATF4 and ATF6β in response to hypoxia–reoxygenation. (A) Hypoxia–reoxygenation
(H/R) suppresses PlGF mRNA: BeWo and JEG-3 cells were cultured under serum-free conditions and subjected to repetitive H/R in a 6 h
cyclic pattern between 1% O2 and 10% O2 for 24 h; the control cells were incubated at both 20% and 10% O2; PlGF mRNA relative levels
were measured by qPCR. (B) ATF4 and ATF6β, but not ATF6α, partially regulates PlGF mRNA level: BeWo cells were transfected with siATF4,
siATF6α, siATF6β or, in combination siATF4+ATF6β and siATF6α+ siATF6β, while non-targeting gene control (siCon) for 48 h prior to being
subjected to H/R conditions for 24 h; relative levels of PlGF mRNA were analysed by qPCR; data are expressed as mean± SEM; n= 4;
**p< 0.01. (C) Flow chart showing the potential mechanisms by which ischaemia–reperfusion-induced placental ER and oxidative stress
may modulate maternal endothelial cell function through regulation of PlGF, VEGF-A and sFlt1 levels
Discussion
Maternal circulating PlGF increases as pregnancy
advances, reaching a peak at around 29–32 weeks
before declining thereafter [18]. In pregnancies com-
plicated with early-onset pre-eclampsia and growth
restriction, circulating PlGF concentrations are lower
throughout gestation compared to normal controls
[18,51,52]. The reduction of circulating PlGF is much
more pronounced compared to age-matched controls in
early-onset pre-eclampsia than in the late-onset form
of the syndrome [53]. Ranking the three pathologies
according to their circulating PlGF levels reveals that
early-onset pre-eclampsia has the lowest concentra-
tion, followed by growth restriction and late-onset
pre-eclampsia. These clinical observations suggest a
negative relationship between the severity of placental
ER stress and the maternal circulating PlGF level. In
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this study, we demonstrate that PlGF is indeed regulated
at the transcriptional level by the UPR transcription
factors ATF4 and ATF6β, resulting in a reduction of
PlGF secretion.
A limitation of our study is that we were not able to
compare the pathological placentae with age-matched
controls. Most pre-term deliveries of normotensive
pregnancies occur by vaginal delivery, due to conditions
such as chorioamnionitis. These placentae display high
levels of ER stress, due to either the underlying pathol-
ogy or the delivery process [35], and so are not suitable
as controls in this setting. Obtaining normal placentae
delivered by caesarean section at 25 weeks, the earliest
pathological cases studied here, is almost impossible
ethically. Nonetheless, we do not consider that our
findings can be attributed to differences in gestational
age. First, concentrations of PlGF fall in late gestation,
as described above, and so would be expected to be
lower, rather than higher, in the term controls. Second,
the strong negative correlation between between PlGF
and ATF4 mRNAs shown in Figure 2B is independent
of gestational age and placental pathology.
Due to the unique role of PlGF in the modulation
of VEGF-A signalling during endothelial cell home-
ostasis and angiogenesis, especially in a stressed envi-
ronment [54], the low circulating PlGF concentration
is widely accepted as one of the key contributors to
maternal endothelial cell dysfunction in pre-eclampsia
[3,20,51]. Surprisingly, another key angiogenic factor,
VEGF-A, is increased in the circulation of pre-eclamptic
patients [55]. This may also reflect placental ER stress,
since ATF4 and IRE1α positively regulate VEGF gene
expression [35,56]. However, the biological activity of
VEGF-A is complicated by the fact that it is largely
bound to its antagonist sFlt1, which is also elevated.
Consequently, there is a reduction in free circulating
VEGF-A, further compromisingmaternal vascular func-
tion [24]. Placental oxidative stress induces secretion of
sFlt1 through p38 kinase signalling [57]. ER stress also
activates p38 kinase via the IRE1α–TRAF2 pathway
[58,59], thereby potentially contributing to modulation
of sFlt1 secretion.
All three UPR pathways are strongly activated in
placentae from early-onset pre-eclampsia, but to only
subtle degrees in late-onset cases [32]. Our results are
thus consistent with the remarkable increase of maternal
circulating sFlt1 and reduction of PlGF in early-onset
pre-eclampsia, and the minimal changes seen in the
late-onset form of the syndrome [53]. Taken together,
these findings suggest a potential vital role of placental
ER stress in the modulation of maternal endothelial cell
function via regulation of the synthesis and secretion of
pro-angiogenic and anti-angiogenic factors in response
to haemodynamic challenges (Figure 6).
The exact mechanism of the synergistic inhibitory
effect of ATF4 andATF6β in the regulation of PlGF tran-
scription remains to be elucidated. However, a recent
study reported that there are two functional cAMP
responsive elements (CREs) in the PlGF promoter, and
that the CREBs can up-regulate PlGF gene expression
upon cAMP stimulation [30]. Coincidently, ATF4 and
ATF6β are also known as cAMP-responsive element
binding protein 2 (CREBP2) and cAMP-responsive
element-binding protein-like 1 (CREBPL-1), respec-
tively. They belong to a family of DNA-binding proteins
including the AP-1 family of transcription factors,
cAMP-response element binding proteins (CREBs) and
CREB-like proteins, indicating their potential inter-
action with CREs. Although both ATF6α and ATF6β
show high structural similarity to each other, undergo
the same proteolytic cleavage to generate their activated
forms and bind to the same regulatory elements, they
exhibit isoform-specific transcriptional activation and
stability characteristics [60,61]. Activated ATF6β is a
relatively poor inducer of UPR response genes, but has
much greater stability than activated ATF6α [60,61].
An in vitro DNA-binding experiment demonstrated
that recombinant activated ATF6β inhibits the binding
of recombinant activated ATF6α to an UPR response
element from the target gene promoter [49]. We there-
fore speculate that one of the potential mechanisms is
ATF4 and ATF6β act synergistically to interact directly
or indirectly with CRE in the PlGF promoter, thereby
inhibiting CREBs-mediated PlGF transcription. This
hypothesis is supported by the observation that the
increase of both placental and maternal circulating
adrenomedullin, a ligand that increases intracellular
cAMP via G-protein-coupled receptors and adenylate
cyclase, in pre-eclampsia does not result in the expected
rise in PlGF [62,63].
The majority of secreted proteins are glycoproteins,
and glycosylation is crucial for their stability, functional
activity and half-life in the circulation [64]. Our previous
publication demonstrated that glycosylation of secreted
proteins is altered upon ER stress, and that their activity
was compromised [65]. PlGF contains two glycosyla-
tion sites, and so its activity is expected to be influenced
by ER stress. Therefore, we speculate that ER stress not
only suppresses PlGF transcription but may also modu-
late its bioactivity. Further experiments will be required
to address this hypothesis. Furthermore, ER stress could
also affect the fetal vasculature of the placenta through
modulation of the expression and activities of the PlGF
and VEGF receptors, VEGFR1 and VEGFR2/KDR.
In placentae from early-onset pre-eclampsia, immunos-
taining of ATF4 and ATF6α was also increased in
the endothelial cells of the fetal capillaries, indicating
the existence of ER stress in these vessels (Figure 1).
VEGFR1 and VEGFR2 are present in both the syncy-
tiotrophoblast and the capillary endothelial cells [66],
and VEGFR2 expression is decreased in pre-eclamptic
placentae [67]. A recent study reported that administra-
tion of an ER stress inducer (tunicamycin) to pregnant
mice is associated with a reduction of VEGFR1 and
VEGFR2 mRNA expression in the placenta [68], sug-
gesting a potential role for ER stress in regulation of
these receptors. Additionally, it has been demonstrated
that the glycosylation of VEGFR2 is crucial for its activ-
ity [69], and likely to be influenced by ER stress. Indeed,
in placentae from pre-eclampsia, VEGFR1 (Flt1) and
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endoglin are hyperglycosylated compared to normoten-
sive control placentae [20].
To conclude, our previous publications demonstrated
that in cases of early-onset pre-eclampsia and FGR pla-
cental ER stress causes protein synthesis inhibition that
contributes to the growth-restricted phenotype. In this
study, we reveal that another consequence of placen-
tal ER stress is the down-regulation of PlGF transcrip-
tion, which is likely to contribute to the reduction in
maternal circulating PlGF, which in turn may modu-
late maternal endothelial cell function and thereby con-
tribute to the pathophysiology of the syndrome. These
new findings further support the concept that allevia-
tion of placental ER stress may provide a new therapeu-
tic target for the treatment of early-onset pre-eclampsia
and FGR.
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